Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Hugo Arasanz; Luisa Chocarro; Leticia Fernández-Rubio; Ester Blanco; Ana Bocanegra; Miriam Echaide; Ibone Labiano; Ana Elsa Huerta; Maria Alsina; Ruth Vera; David Escors; Grazyna Kochan

doi:10.3390/ijms24129855

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Int J Mol Sci. 2023 Jun 7;24(12):9855. doi: 10.3390/ijms24129855.

Authors

Hugo Arasanz^{1

2}, Luisa Chocarro³, Leticia Fernández-Rubio³, Ester Blanco^{3

4}, Ana Bocanegra³, Miriam Echaide³, Ibone Labiano², Ana Elsa Huerta², Maria Alsina^{1

2}, Ruth Vera^{1

2}, David Escors³, Grazyna Kochan³

Affiliations

¹ Medical Oncology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
² Oncobiona Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
³ Oncoimmunology Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
⁴ Division of Gene Therapy and Regulation of Gene Expression, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.

Abstract

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

Keywords: NSCLC; SCLC; bispecific; lung cancer; nanobodies; targeted therapies.

Publication types

Review

MeSH terms

Antibodies, Bispecific* / therapeutic use
Humans
Immunotherapy
Lung Neoplasms* / pathology

Substances

Antibodies, Bispecific

Grants and funding

D.E. is funded by a Miguel Servet Fellowship (ISC III, CP12/03114, Spain). H.A. is supported by the Clínico Junior 2019 scholarship from the AECC (CLJUN19010ARAS). I.L. is financed by National Agency of Research (AEI) in the “Juan de la Cierva-Postdoctoral formación” (8FJC2021-046521-I). L.C. is financed by Instituto de Salud Carlos III (ISCIII), co-financed by FEDER funds, “Contratos PFIS: contratos predoctorales de formación en investigación en salud” (FI21/00080). M.A. is partially financed by the Government of Navarra in the La Caixa Program.